{"story":{"id":1291857,"title":"ESMO 2026: ctDNA Analysis of the Phase 3 KEYNOTE-B15 Trial: Neoadjuvant and Adjuvant Enfortumab Vedotin Plus Pembrolizumab for Participants With Muscle-Invasive Bladder Cancer Who Are Eligible for Cisplatin - UroToday","permalink":"https://checknews.org/historia.php?id=1291857","status":"quiet","category":"science","country":"ET","country_name":"Ethiopia","language":"en","first_seen_at":"2026-10-23T17:42:51-06:00","last_activity_at":"2026-10-23T17:42:51-06:00","source_count":1,"article_count":1,"image":null,"articles":[{"title":"ESMO 2026: ctDNA Analysis of the Phase 3 KEYNOTE-B15 Trial: Neoadjuvant and Adjuvant Enfortumab Vedotin Plus Pembrolizumab for Participants With Muscle-Invasive Bladder Cancer Who Are Eligible for Cisplatin - UroToday","publisher":"UroToday","url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPMGJubk11R0JNc0JTelFlWVVTY25QT0RMRnVBLUR3dm1WemNjLTkyOUhlOHh2aDc0djc0RF9uZm93YlQtdzh4YlNKVi10XzhIRzFLS1JMMVNaRlNiT0RzZkU1Um1IRGtJcXkyODV6Y0NWbi1oV3lZOWxkZmE4bmQ2cnhZYUE2aDIyMVYxb1kyQzd6RmpPaW13Yk5najRuRW5SR01pUkxOT3NRN20taUlnRUFFbU1PRU9acUNoaVpDRF9hbmNhQ3NVTGFaYmF5U0J4ZkU1SU13ZmVMVUxaT0h2VzZCVjU3Zw?oc=5","country":"ET","country_name":"Ethiopia","language":"en","published_at":"2026-10-23T17:42:51-06:00"}],"source_url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPMGJubk11R0JNc0JTelFlWVVTY25QT0RMRnVBLUR3dm1WemNjLTkyOUhlOHh2aDc0djc0RF9uZm93YlQtdzh4YlNKVi10XzhIRzFLS1JMMVNaRlNiT0RzZkU1Um1IRGtJcXkyODV6Y0NWbi1oV3lZOWxkZmE4bmQ2cnhZYUE2aDIyMVYxb1kyQzd6RmpPaW13Yk5najRuRW5SR01pUkxOT3NRN20taUlnRUFFbU1PRU9acUNoaVpDRF9hbmNhQ3NVTGFaYmF5U0J4ZkU1SU13ZmVMVUxaT0h2VzZCVjU3Zw?oc=5","publishers":[{"name":"UroToday","country":"ET","country_name":"Ethiopia"}],"countries":["ET"]},"generated_at":"2026-11-17T01:19:56-06:00"}